Company Overview of Arisaph Pharmaceuticals, Inc.
Arisaph Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing therapies for cancer, cardiovascular disease, and diabetes. Its products include dipeptidylpeptidase IV inhibitors, stable GLP-1 agonists, HDL modulators and plaque reducers, and tumor activated pro-soft drugs. Arisaph Pharmaceuticals, Inc. was formerly known as Triad Pharmaceuticals, Inc. and changed its name to Arisaph Pharmaceuticals, Inc. in November 2005. The company was incorporated in 1999 and is based in Boston, Massachusetts.
100 High Street
Boston, MA 02110
Founded in 1999
Key Executives for Arisaph Pharmaceuticals, Inc.
Similar Private Companies By Industry
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
|7 Oaks Pharmaceutical Corp.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Bloomberg L.P.||United States|
Sponsored Financial Commentaries
To contact Arisaph Pharmaceuticals, Inc., please visit www.arisaph.com. Company data is provided by Capital IQ. Please use this form to report any data issues.